Gérard Ber

Dr. Gérard Ber is a Director and a member of both the Compensation Committee and the Science and Technology Committee, serving on the Board of Directors since June 2020. Dr. Ber is also a member of the board of Y-mAbs Therapeutics, Inc. He served on the board of directors of Progenics Pharmaceuticals, Inc. until its acquisition by the Company. Dr. Ber was also the Co-Founder and former Chief Operating Officer of Advanced Accelerator Applications S.A. until its acquisition by Novartis AG. He brings over 30 years of experience in molecular nuclear medicines, specifically including product development, production and commercialization of diagnostics and therapeutic products for several indications in various diseases.